Advertisement
Canada markets open in 3 hours 53 minutes
  • S&P/TSX

    24,471.17
    +168.87 (+0.69%)
     
  • S&P 500

    5,859.85
    +44.82 (+0.77%)
     
  • DOW

    43,065.22
    +201.36 (+0.47%)
     
  • CAD/USD

    0.7242
    -0.0007 (-0.10%)
     
  • CRUDE OIL

    70.33
    -3.50 (-4.74%)
     
  • Bitcoin CAD

    90,740.79
    +1,552.02 (+1.74%)
     
  • XRP CAD

    0.75
    +0.01 (+1.29%)
     
  • GOLD FUTURES

    2,671.00
    +5.40 (+0.20%)
     
  • RUSSELL 2000

    2,248.64
    +14.23 (+0.64%)
     
  • 10-Yr Bond

    4.0980
    +0.0250 (+0.61%)
     
  • NASDAQ futures

    20,584.25
    -35.00 (-0.17%)
     
  • VOLATILITY

    19.74
    +0.04 (+0.20%)
     
  • FTSE

    8,263.50
    -29.16 (-0.35%)
     
  • NIKKEI 225

    39,910.55
    +304.75 (+0.77%)
     
  • CAD/EUR

    0.6638
    -0.0004 (-0.06%)
     

HSIC Stock Likely to Get a Boost From New Henry Schein One Launches

Henry Schein’s HSIC dental software business, Henry Schein One, has introduced two new tools — Eligibility Essentials and Eligibility Pro — to simplify the insurance eligibility process for dental practices. Currently available for Dentrix and Dentrix Ascend cloud-based practice management solutions, the new tools are designed to help foster trust between dental practices and patients by reducing insurance-related surprises.

Henry Schein One is the largest component in the company’s Technology and value-added services segment. The latest development reflects its goal to provide practices with detailed benefit information, enabling accurate discussions about treatment plans and financial responsibilities with patients.

Following the release of the news, shares of HSIC rose by 0.6%, closing at $69.86 on Thursday. These new offerings are likely to prove highly synergetic in strengthening the company’s foothold within the promising dental software market. We expect market sentiment to continue to remain positive about the stock.

New Henry Schein One Tools Enhance Insurance Verification

The verification of insurance eligibility has traditionally been a time-consuming process, with dental staff members spending valuable time logging into patient portals and calling payors for eligibility data one patient at a time. The standard Electronic Data Interchange connections often do not deliver responses from many payors, and when they do, the information is often incomplete. This forces staff to call helplines or access payor portals for necessary coverage data.

Eligibility Essentials empowers dental practices with fast, accurate coverage insights — all within the trusted platform the dental profession has come to rely on. It streamlines access to accurate, up-to-date insurance data from an extensive network of payors in a standardized PDF format. This consistency makes it easy to find and use the necessary information for treatment planning.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

Taking insurance verification to the next level, Eligibility Pro unlocks more benefits data by delivering information from payor portals in addition to the EDI data provided by Essentials. By removing the need to log into multiple insurance portals, the dental staff saves valuable time, and treatment plan acceptance may improve since patients better understand their coverage and out-of-pocket expenses.

Industry Prospects Favoring HSIC

Per a Grand View Research report, the global dental practice management software market was valued at $2.6 billion in 2023 and is expected to witness a compound annual rate of 10.2% by 2030. The market growth is expected to be fueled by the increasing dental visits, growing focus and awareness about oral health in Europe and the United States and rapid technological advancements.

The adoption of healthcare IT solutions, especially by specialty clinics such as oral practices, is anticipated to grow insurance coverage. These will further boost the demand for oral services, driving the need for dental practice management software.

Recent Developments of Henry Schein

In July 2024, HSIC acquired abc dental AG — a Swiss-based, full-service dental distributor offering consumables, equipment and technical services to general practitioners, specialists and dental laboratories. The investment furthers the company’s strategic vision to become the leading full-service distributor in Switzerland. The transaction is expected to be neutral to 2024 non-GAAP earnings per share and accretive thereafter.

HSIC Stock Price Performance

Over the past year, shares of the company have declined 7.3% compared with the industry’s 2.6% fall.

HSIC Estimate Trend and EPS Surprise

Henry Schein’s earnings estimates have decreased by 3.7% for 2024 and by 2.8% for 2025 in the past 30 days. In the trailing four quarters, the company surpassed estimates twice, broke even on one and missed on one occasion, the average surprise being 1.6%.

HSIC’s Zacks Rank and Top MedTech Picks

Henry Schein currently carries a Zacks Rank #4 (Sell).

Some better-ranked stocks in the broader medical space are Boston Scientific BSX, AxoGen AXGN and SiBone SIBN, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Boston Scientific’s shares have risen 51.5% in the past year. Estimates for the company’s earnings per share have remained constant at $2.40 in 2024 and $2.71 in 2025 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.2%. In the last reported quarter, it posted an earnings surprise of 6.9%.

Estimates for AxoGen’s 2024 loss per share have narrowed to 1 cent from 19 cents in the past 30 days. Shares of the company have surged 123.7% in the past year compared with the industry’s growth of 12.8%. AXGN’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.5%. In the last reported quarter, it delivered an earnings surprise of 200%.

Estimates for SiBone’s 2024 loss per share have remained constant at 89 cents in the past 30 days. Shares of the company have dropped 30.5% in the past year against the industry’s 12.8% growth. SIBN’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.4%. In the last reported quarter, it delivered an earnings surprise of 15.4%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Boston Scientific Corporation (BSX) : Free Stock Analysis Report

Henry Schein, Inc. (HSIC) : Free Stock Analysis Report

AxoGen, Inc. (AXGN) : Free Stock Analysis Report

SiBone (SIBN) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research